.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,855,190

« Back to Dashboard

Claims for Patent: 7,855,190

Title:Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
Abstract:The present invention provides contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin followed by a period of administration of estrogen. The disclosed contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits.
Inventor(s): Bell; Robert G. (Palm Harbor, FL), Ben-Maimon; Carole S. (Merion, PA), Iskold; Beata (Livingston, NJ), Bronnenkant; Lance J. (Snyder, NY), Hait; Howard (Wilmington, DE), Reape; Kathleen Z. (Bryn Mawr, PA)
Assignee: Teva Women's Health, Inc. (Woodcliff Lake, NJ)
Application Number:10/892,404
Patent Claims: 1. A method of increasing contraceptive effectiveness in a higher weight female in need thereof, the method comprising administering to the female a dosage comprising a combination of estrogen and progestin for a period of more than 50 consecutive days, followed by administration of a dosage consisting essentially of estrogen for a period of 2 to 10 consecutive days, wherein the estrogen that is administered in combination with progestin for the period of more than 50 consecutive days is administered in a daily amount equivalent to about 10 .mu.g to about 30 .mu.g of ethinyl estradiol, the estrogen that is administered for the period of 2 to 10 consecutive days is administered in a daily amount equivalent to about 10 .mu.g to about 30 .mu.g of ethinyl estradiol, and the progestin that is administered for the period of more than 50 consecutive days is administered in a daily amount equivalent to about 0.02 mg to about 1.5 mg of levonorgestrel, and wherein the higher weight female weighs about 70 kg or more.

2. The method of claim 1, wherein the dosage comprising the combination of estrogen and progestin is administered for a period of 81 to 89 consecutive days.

3. The method of claim 2, wherein the dosage comprising the combination of estrogen and progestin is administered for 84 consecutive days.

4. The method of claim 1, wherein the dosage consisting essentially of estrogen is administered for a period of 5 to 8 consecutive days.

5. The method of claim 4, wherein the dosage consisting essentially of estrogen is administered for 7 consecutive days.

6. The method of claim 1, wherein the dosage comprising the combination of estrogen and progestin is administered for 84 consecutive days, and the dosage consisting essentially of estrogen is administered for 7 consecutive days.

7. The method of claim 1, wherein the estrogen that is administered for the period of more than 50 consecutive days is administered in a daily amount equivalent to about 20 .mu.g of ethinyl estradiol.

8. The method of claim 1, wherein the estrogen that is administered for the period of more than 50 consecutive days is administered in a daily amount equivalent to about 30 .mu.g of ethinyl estradiol.

9. The method of claim 1, wherein the estrogen that is administered for the period of 2 to 10 consecutive days is administered in a daily amount equivalent to about 10 .mu.g of ethinyl estradiol.

10. The method of claim 1, wherein the estrogen that is administered for the period of 2 to 10 consecutive days is administered in a daily amount equivalent to about 30 .mu.g of ethinyl estradiol.

11. The method of claim 1, wherein the estrogen is ethinyl estradiol.

12. The method of claim 1, wherein the progestin that is administered for the period of more than 50 consecutive days is administered in a daily amount equivalent to about 0.05 mg to about 0.20 mg of levonorgestrel.

13. The method of claim 1, wherein the progestin that is administered for the period of more than 50 consecutive days is administered in a daily amount equivalent to about 0.15 mg of levonorgestrel.

14. The method of claim 1, wherein the progestin that is administered for the period of more than 50 consecutive days is administered in a daily amount equivalent to about 0.10 mg of levonorgestrel.

15. The method of claim 1, wherein the progestin that is administered for the period of more than 50 consecutive days is levonorgestrel.

16. The method of claim 1, wherein the progestin that is administered for the period of more than 50 consecutive days is desogestrel.

17. The method of claim 1, wherein an antidepressant is administered (i) in combination with the dosage consisting essentially of estrogen for the period of 2 to 10 consecutive days, (ii) intermittently, (iii) one time, or (iv) once weekly.

18. The method of claim 1, wherein the dosage comprising the combination of estrogen and progestin that is administered for the period of more than 50 consecutive days, and the dosage consisting essentially of estrogen that is administered for the period of 2 to 10 consecutive days, are administered orally.

19. The method of claim 1, wherein the dosage comprising the combination of estrogen and progestin that is administered for the period of more than 50 consecutive days, and the dosage consisting essentially of estrogen that is administered for the period of 2 to 10 consecutive days, are administered transdermally.

20. The method of claim 1, wherein the dosage comprising the combination of estrogen and progestin that is administered for the period of more than 50 consecutive days, and the dosage consisting essentially of estrogen that is administered for the period of 2 to 10 consecutive days, are administered monophasically.

21. The method of claim 1, wherein the higher weight female weighs about 80 kg or more.

22. The method of claim 1, wherein the higher weight female weighs about 90 kg or more.

23. The method of claim 1, wherein the higher weight female has a body mass index of greater than about 25.

24. The method of claim 1, wherein the higher weight female has a body mass index of greater than about 30.

25. The method of claim 1, wherein the higher weight female has a body mass index of greater than about 35.

26. A method of increasing contraceptive effectiveness in a higher weight female in need thereof, the method comprising administering to the female a dosage comprising a combination of estrogen and progestin for a period of 84 consecutive days, followed by administration of a dosage consisting essentially of estrogen for a period of 7 consecutive days, wherein the estrogen that is administered in combination with progestin for the period of 84 consecutive days is administered in a daily amount of about 10 .mu.g to about 30 .mu.g of ethinyl estradiol, the estrogen that is administered for the period of 7 consecutive days is administered in a daily amount of about 10 .mu.g of ethinyl estradiol, and the progestin that is administered in combination with estrogen for the period of 84 consecutive days is administered in a daily amount of about 0.05 mg to about 0.15 mg of levonorgestrel, wherein the higher weight female weighs about 70 kg or more.

27. A method of increasing contraceptive effectiveness in a higher weight female in need thereof, the method comprising administering to the female a dosage comprising a combination of estrogen and progestin for a period of 84 consecutive days, followed by administration of a dosage consisting essentially of estrogen for a period of 7 consecutive days, wherein the estrogen that is administered in combination with progestin for the period of 84 consecutive days is administered in a daily amount of about 30 .mu.g of ethinyl estradiol, the estrogen that is administered for the period of 7 consecutive days is administered in a daily amount of about 10 .mu.g of ethinyl estradiol, and the progestin that is administered in combination with estrogen for the period of 84 consecutive days is administered in a daily amount of about 0.15 mg of levonorgestrel, wherein the higher weight female weighs about 70 kg or more.

28. A method of increasing contraceptive effectiveness in a higher weight female in need thereof, the method comprising administering to the female a dosage comprising a combination of estrogen and progestin for a period of 84 consecutive days, followed by administration of a dosage consisting essentially of estrogen for a period of 7 consecutive days, wherein the estrogen that is administered in combination with progestin for the period of 84 consecutive days is orally administered monophasically in a daily amount of about 30 .mu.g of ethinyl estradiol, the estrogen that is administered for the period of 7 consecutive days is orally administered monophasically in a daily amount of about 10 .mu.g of ethinyl estradiol, and the progestin that is administered in combination with estrogen for the period of 84 consecutive days is orally administered monophasically in a daily amount of about 0.15 mg of levonorgestrel, wherein the higher weight female weighs about 70 kg or more.

29. A method of increasing contraceptive effectiveness in a higher weight female in need thereof, the method comprising administering to the female a dosage comprising a combination of estrogen and progestin for a period of 84 consecutive days, followed by administration of a dosage consisting essentially of estrogen for a period of 7 consecutive days, wherein the estrogen that is administered in combination with progestin for the period of 84 consecutive days is administered in a daily amount of about 20 .mu.g of ethinyl estradiol, the estrogen that is administered for the period of 7 consecutive days is administered in a daily amount of about 10 .mu.g of ethinyl estradiol, and the progestin that is administered in combination with estrogen for the period of 84 consecutive days is administered in a daily amount of about 0.10 mg of levonorgestrel, wherein the higher weight female weighs about 70 kg or more.

30. A method of increasing contraceptive effectiveness in a higher weight female in need thereof, the method comprising administering to the female a dosage comprising a combination of estrogen and progestin for a period of 84 consecutive days, followed by administration of a dosage consisting essentially of estrogen for a period of 7 consecutive days, wherein the estrogen that is administered in combination with progestin for the period of 84 consecutive days is orally administered monophasically in a daily amount of about 20 .mu.g of ethinyl estradiol, the estrogen that is administered for the period of 7 consecutive days is orally administered monophasically in a daily amount of about 10 .mu.g of ethinyl estradiol, and the progestin that is administered in combination with estrogen for the period of 84 consecutive days is orally administered monophasically in a daily amount of about 0.10 mg of levonorgestrel, wherein the higher weight female weighs about 70 kg or more.

31. A method of increasing contraceptive effectiveness in a higher weight female in need thereof, the method comprising administering to the female a dosage comprising a combination of estrogen and progestin for a period of 84 consecutive days, followed by administration of a dosage consisting essentially of estrogen for a period of 7 consecutive days, wherein the estrogen that is administered in combination with progestin for the period of 84 consecutive days is administered in a daily amount of about 30 .mu.g of ethinyl estradiol, the estrogen that is administered for the period of 7 consecutive days is administered in a daily amount of about 30 .mu.g of ethinyl estradiol, and the progestin that is administered in combination with estrogen for the period of 84 consecutive days is administered in a daily amount of about 0.15 mg of levonorgestrel, wherein the higher weight female weighs about 70 kg or more.

32. A method of increasing contraceptive effectiveness in a higher weight female in need thereof, the method comprising administering to the female a dosage comprising a combination of estrogen and progestin for a period of 84 consecutive days, followed by administration of a dosage consisting essentially of estrogen for a period of 7 consecutive days, wherein the estrogen that is administered in combination with progestin for the period of 84 consecutive days is orally administered monophasically in a daily amount of about 30 .mu.g of ethinyl estradiol, the estrogen that is administered for the period of 7 consecutive days is orally administered monophasically in a daily amount of about 30 .mu.g of ethinyl estradiol, and the progestin that is administered in combination with estrogen for the period of 84 consecutive days is orally administered monophasically in a daily amount of about 0.15 mg of levonorgestrel, wherein the higher weight female weighs about 70 kg or more.

33. A method of increasing contraceptive effectiveness in a higher weight female in need thereof, the method comprising administering to the female a dosage comprising a combination of estrogen and progestin for a period of 21 consecutive days, followed by administration of a dosage consisting essentially of estrogen for a period of 7 consecutive days, wherein the estrogen that is administered in combination with progestin for the period of 21 consecutive days is administered in a daily amount of about 20 .mu.g of ethinyl estradiol, the estrogen that is administered for the period of 7 consecutive days is administered in a daily amount of about 10 .mu.g of ethinyl estradiol, and the progestin that is administered for the period of 21 consecutive days is administered in a daily amount of about 0.15 mg of desogestrel, and wherein the higher weight female weighs about 70 kg or more.

34. The method of claim 33, wherein an antidepressant is administered (i) in combination with the dosage consisting essentially of estrogen for the period of 7 consecutive days, (ii) intermittently, (iii) one time, or (iv) once weekly.

35. The method of claim 33, wherein the dosage comprising the combination of estrogen and progestin that is administered for the period of 21 consecutive days, and the dosage consisting essentially of estrogen that is administered for the period of 7 consecutive days, are administered orally.

36. The method of claim 33, wherein the dosage comprising the combination of estrogen and progestin that is administered for the period of 21 consecutive days, and the dosage consisting essentially of estrogen that is administered for the period of 7 consecutive days, are administered transdermally.

37. The method of claim 33, wherein the dosage comprising the combination of estrogen and progestin that is administered for the period of 21 consecutive days, and the dosage consisting essentially of estrogen that is administered for the period of 7 consecutive days, are administered monophasically.

38. The method of claim 33, wherein the higher weight female weighs about 80 kg or more.

39. The method of claim 33, wherein the higher weight female weighs about 90 kg or more.

40. The method of claim 33, wherein the higher weight female has a body mass index of greater than about 25.

41. The method of claim 33, wherein the higher weight female has a body mass index of greater than about 30.

42. The method of claim 33, wherein the higher weight female has a body mass index of greater than about 35.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc